Portola Pharmaceuticals Inc. (PTLA)

Trade PTLA now with
5/14/2020 8:22:23 AM U.S. Centers For Medicare & Medicaid Services Proposes Extending New Technology Add-on Payment For Andexxa Thro 2021
5/11/2020 8:12:09 AM Portola Pharma Q1 Net Loss Attributable To Portola $68.8 Mln Or $0.88/Shr Vs Loss $78.2 Mln Or $1.17/Shr Last Year
4/7/2020 8:18:37 AM Portola Announces Establishment Of A Permanent J-code For Andexxa By The Centers For Medicare & Medicaid Services
2/3/2020 8:34:07 AM Portola Pharma Names Rajiv Patni EVP And Chief Medical Officer
2/3/2020 8:32:52 AM Portola Pharmaceuticals Appoints Rajiv Patni EVP And Chief Medical Officer
10/28/2019 9:10:28 AM Portola Says Effective Hemostasis Achieved In 82% Of Evaluable Patients With Acute Gastrointestinal Bleeding
9/19/2019 8:21:53 AM Portola Pharma Appoints Ted Love To Board
8/12/2019 4:49:06 PM Portola Pharmaceuticals Announces Proposed Offering Of Common Stock
8/6/2019 8:32:42 AM Portola Launches European Sales Of Ondexxya With First Orders In Europe
7/8/2019 8:35:42 AM Portola : Vitro Data Shows 4F-PCCs No Direct Effect On Inhibition Of Thrombin Generation By Factor Xa Inhibitors
1/28/2019 9:23:57 AM Portola Appoints Sheldon Koenig As EVP And Chief Commercial Officer
12/31/2018 3:44:14 PM FDA OKs Portola Pharma's Approval Supplement For Andexxa Generation 2 Manufacturing Process
12/11/2018 7:03:46 AM CHMP Extends Review Period For Portola Pharmaceuticals’ Ondexxya To February 28, 2019
12/3/2018 9:32:06 PM Portola Updates Interim Results From Ongoing Phase 2a Study Of Cerdulatinib